Skip to main content

Equibles does not estimate personal net worth.

Get an email with a short summary when Heron Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.

Get HRTX alerts

About William Forbes

Heron Therapeutics, Inc. reported in an 8-K filed June 12, 2023 that William Forbes was appointed Executive Vice President, Chief Development Officer, effective June 6, 2023. The proxy statement of Heron Therapeutics, Inc. reports total compensation of $1,687,765 for William Forbes in fiscal 2025, including a base salary of $609,881. Disclosed compensation is on record for 4 fiscal years. Heron Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Heron Therapeutics, Inc. includes Craig Collard (CEO and Board Member), Adam Morgan (Chairman and Board Member), Ira Duarte (CFO and Chief Accounting Officer) and 7 others.

“effective as of June 6, 2023, William Forbes joined the Company as Executive Vice President, Chief Development Officer.”
Heron Therapeutics, Inc. Form 8-K, filed June 12, 2023 · Read the filing

Affiliation history

Company network

Leadership on record at Heron Therapeutics, Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Heron Therapeutics, Inc. (HRTX) $609,881 $1,687,765
2024 Heron Therapeutics, Inc. (HRTX) $592,250 $1,536,130
2023 Heron Therapeutics, Inc. (HRTX) $329,519 $1,458,106
2022 Heron Therapeutics, Inc. (HRTX) — —

Recent activity